Episode Details

In this episode of The BioHub Podcast, Max sits down with Bruce Leuchter, co-founder and CEO of Neurvati Neurosciences.

Bruce’s career spans clinical neuroscience, psychiatry, investment banking, and biotech company building — giving him a uniquely broad perspective on the future of CNS drug development.

Neurvati, a Blackstone Life Sciences portfolio company, is focused on identifying and advancing high-potential therapies for neurological and psychiatric disorders.

In this conversation, we discuss the evolving neuroscience landscape, how to choose the right assets and modalities, the differences between public and private markets in neuro, and why building the right team is so critical in biotech.

A thoughtful conversation about one of the most challenging — and exciting — areas in medicine.